Compare BioNTech SE - ADR (BNTX) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Krispy Kreme Inc — how do they compare? BioNTech SE - ADR trades at $90.38 (market cap $22.86B), while Krispy Kreme Inc trades at $3.31 (market cap $574.09M). The key difference: BioNTech SE - ADR is far larger — about 39.8× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | DNUT | |
|---|---|---|
Market Cap | $22.86B | $574.09M |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $4.70 |
52-Week Low | $83.89 | $2.92 |
Enterprise Value | $6.53B | $1.77B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Krispy Kreme (DNUT) trades at $3.47, up 0.87% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of $515.77M in 2025 despite a gross margin of 75.56%, while analyst consensus leans bullish with 50% buy ratings. Recent news highlights strategic pivots to capital-light models and seasonal product launches to drive engagement.
Outlook remains challenged by persistent losses and high debt, but positive free cash flow in Q1 2026 and international growth potential offer catalysts. Key risks include execution on turnaround plans and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
